Tegoprubart is under clinical development by Eledon Pharmaceuticals and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tegoprubart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tegoprubart overview
Eledon Pharmaceuticals overview
Eledon Pharmaceuticals is a is a clinical stage biotechnology company that is develops immune-modulating therapies. It focuses on kidney transplantation. The company’s pipeline products include Tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. Tegoprubart is used for the treatment of kidney transplantation, liver transplantation, xenotransplantation, amyotrophic lateral, sclerosis (ALS), islet cell transplantation. It also targets he CD40L in patients with autoimmune and neurodegenerative diseases. The company collaborates with pharmaceutical companies. Eledon Pharmaceuticals is headquartered in Irvine, California, the US.
For a complete picture of Tegoprubart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
